StreetAlpha.app
Home › Stocks › LONA

LeonaBio, Inc. (LONA)

Healthcare
$2.80
▼ −13.31%
LAST CLOSE · NOV 17

LeonaBio develops experimental drugs for metastatic breast cancer and ALS, based in Bothell, Washington. It last closed at $2.80 on Nov 17, down 13.31% on the day.

AI Auto Pilots
Is LONA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$156.0M
EPS (diluted)
−$22.20
Valuation
Market cap
$36.6M
13.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$16.3M
At Sep 30
Shareholder equity
$16.0M
Shares outstanding
13.1M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$54.9M−$54.9MFY2021FY2022: −$95.6M−$95.6MFY2022FY2023: −$117.7M−$117.7MFY2023FY2024: −$96.9M−$96.9MFY2024FY2025: −$105.6M−$105.6MFY2025

From LONA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated LONA in the past 90 days, not enough for a consensus
Average 12-month target
$16.00
▲ 471.4% upside

Based on 1 analyst who set a price target on LONA in the past 90 days. The average target is $16.00, with a high of $16.00 and a low of $16.00, compared with the last close of $2.80.

Low $16.00Avg $16.00High $16.00
Blue marker: last close $2.80
Highest target$16.00
Average target$16.00
Lowest target$16.00
Latest rating changes
CitizensTarget lowered
Nov 17Buy$17 → $16
MizuhoMaintained
Aug 19Buy$15
CitizensTarget lowered
Aug 17Buy$18 → $17
CitizensUpgrade
Jul 30Buy$18
Piper SandlerInitiated
May 27Buy$20
DateFirmActionRatingPrice target
Nov 17CitizensTarget loweredBuy$17 → $16
Aug 19MizuhoMaintainedBuy$15
Aug 17CitizensTarget loweredBuy$18 → $17
Jul 30CitizensUpgradeBuy$18
May 27Piper SandlerInitiatedBuy$20
Loading…

Technical Analysis

LONA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 58% below its 20 day and 84% below its 50 day average. It is 165% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot S1 at $2.70, and the nearest resistance the Pivot at $2.85.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 18.6%/day
Key levels
$14.2152 week high+407.5%
$7.42200 day average+165.0%
$6.56100 day average+134.3%
$5.40Swing high (Oct 29)+92.9%
$5.1550 day average+83.9%
$4.4220 day average+57.9%
$2.96Pivot R1+5.7%
$2.85Pivot+1.8%
$2.80Last close
$2.70Pivot S1−3.6%
$2.2152 week low−21.1%
$2.21Swing low (Sep 28)−21.1%
Indicators
RSI (14)23.29Oversold below 30Oversold
MACD-0.57Below its signal lineBearish
Stochastic1.2Near the bottom of its rangeOversold
ADX (14)21.7Weak trend
Williams %R-98.1Oversold below −80, overbought above −20Oversold
CCI (20)-202.2Oversold below −100, overbought above 100Oversold
Rate of change−41.3%Change over 10 sessionsBearish
ATR (14)$0.52Typical daily range, 18.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LONA

What happened before

See how LONA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LONA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LONA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LONA in the last 90 days.

Loading…

See today’s whale options flow across the market →

LONA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●13 buying vs 12 selling
  • ▲Held by funds +1.7 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4945+8.9%
In funds' top 1000–
Held by funds60.3%58.6%+1.7 pts
New / increased5 / 87 / 8−13.3%
Reduced / sold out11 / 16 / 3+33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LONA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LONA is in one of them and how their past LONA trades turned out.

LONA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LONA in an article yet. Here's the latest on the wider market.

About LeonaBio

LeonaBio is a biopharmaceutical company based in Bothell, Washington, that develops drug candidates for diseases where current treatments are limited. Its lead candidate, lasofoxifene, is being studied for metastatic breast cancer that has stopped responding well to standard hormone therapy. Its other lead candidate, ATH-1105, is in development for amyotrophic lateral sclerosis, also known as ALS. The company has no approved products yet, and it aims its drugs at patients with these conditions.

Headquarters
Bothell, WA